{"id":24214,"date":"2024-05-06T21:04:24","date_gmt":"2024-05-06T19:04:24","guid":{"rendered":"https:\/\/ggba.swiss\/?p=24214"},"modified":"2024-05-06T21:04:25","modified_gmt":"2024-05-06T19:04:25","slug":"nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/","title":{"rendered":"Nanobacterie secures strategic investment from EP Equity to advance prostate cancer treatment"},"content":{"rendered":"\n<p>Founded in 2008 by Dr. Edouard Alphand\u00e9ry, a leading expert in oncological hyperthermia, <a href=\"http:\/\/www.nanobacterie.fr\/?page_id=177&amp;lang=en\">Nanobacterie<\/a> specializes in non-invasive cancer treatments utilizing magnetic nanoparticles synthesized by magnetotactic bacteria. The company has been at the forefront of developing a novel treatment method and medical device, now poised for clinical trials and regulatory approvals.<\/p>\n\n\n\n<p>The strategic investment from EPEI is a pivotal development for Nanobacterie, providing crucial support as the company moves into the next phase of clinical trials for its prostate cancer treatment. &#8220;EPEI&#8217;s investment is critical for us at this crucial stage of development. Their belief in our mission and technology allows us to move forward with the essential clinical trials needed to bring our treatment to patients,&#8221; said Edouard Alphand\u00e9ry, CEO of Nanobacterie. &#8220;Together, we are setting a new standard in cancer treatment.&#8221;<\/p>\n\n\n\n<figure class=\"wp-block-embed aligncenter is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"Western Switzerland for Precision Oncology Companies (AlphaOnco Swiss)\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/tjQbZa9mw9g?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<p>This partnership comes at a time when Nanobacterie is gearing up to further its research and bring its groundbreaking treatment method to market. The backing by EPEI will enable Nanobacterie to continue its innovative work in this field and potentially extend its technology to other medical conditions in the future.<\/p>\n\n\n\n<p>EP Equity Investment, separate from EP Group\u2019s industrial holdings, focuses on enhancing its portfolio through strategic investments in both publicly traded and private companies. The firm&#8217;s acquisition of a minority stake in Nanobacterie aligns with its strategy to support high-potential businesses that lead in their respective fields.<\/p>\n\n\n\n<p>This strategic move is also a testament to the Franco-Swiss collaboration, as AlphaOnco Swiss, a subsidiary of Nanobacterie based at the <a href=\"https:\/\/www.bioark.ch\/en\/\">BioArk<\/a> in Monthey (canton of Valais), continues to drive forward with its cutting-edge cancer treatment solutions, benefiting from the synergy of extensive research and development supported by their parent company, Nanobacterie, which <a href=\"https:\/\/ggba.swiss\/en\/nanomedicine-pioneer-nanobacterie-achieves-remarkable-patent-ranking\/\">recently achieved remarkable recognition in nanomedicine patent rankings by Marks and Clerk<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>EP Equity Investment (EPEI), a company dedicated to investing in promising European companies, has acquired a 24.99% stake in Nanobacterie to advance the development of innovative treatments for prostate cancer.<\/p>\n","protected":false},"author":6,"featured_media":24215,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[912,894,883,911,901],"class_list":["post-24214","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-biotech","tag-financing","tag-oncology","tag-pharma","tag-technology-park"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanobacterie secures strategic investment from EP Equity | GGBa<\/title>\n<meta name=\"description\" content=\"EP Equity Investment has acquired a 24.99% stake in Nanobacterie to advance the development of innovative treatments for prostate cancer.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanobacterie secures strategic investment from EP Equity | GGBa\" \/>\n<meta property=\"og:description\" content=\"EP Equity Investment has acquired a 24.99% stake in Nanobacterie to advance the development of innovative treatments for prostate cancer.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-05-06T19:04:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-05-06T19:04:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"2360\" \/>\n\t<meta property=\"og:image:height\" content=\"1622\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Nanobacterie secures strategic investment from EP Equity to advance prostate cancer treatment\",\"datePublished\":\"2024-05-06T19:04:24+00:00\",\"dateModified\":\"2024-05-06T19:04:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/\"},\"wordCount\":319,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg\",\"keywords\":[\"Biotech\",\"Financing\",\"Oncology\",\"Pharma\",\"Technology Park\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/\",\"url\":\"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/\",\"name\":\"Nanobacterie secures strategic investment from EP Equity | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg\",\"datePublished\":\"2024-05-06T19:04:24+00:00\",\"dateModified\":\"2024-05-06T19:04:25+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"EP Equity Investment has acquired a 24.99% stake in Nanobacterie to advance the development of innovative treatments for prostate cancer.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg\",\"width\":2360,\"height\":1622,\"caption\":\"As Nanobacterie prepares for clinical trials, EPEI's investment both validates their innovative approach and strengthens their ability to address critical global medical challenges.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanobacterie secures strategic investment from EP Equity to advance prostate cancer treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanobacterie secures strategic investment from EP Equity | GGBa","description":"EP Equity Investment has acquired a 24.99% stake in Nanobacterie to advance the development of innovative treatments for prostate cancer.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/","og_locale":"en_US","og_type":"article","og_title":"Nanobacterie secures strategic investment from EP Equity | GGBa","og_description":"EP Equity Investment has acquired a 24.99% stake in Nanobacterie to advance the development of innovative treatments for prostate cancer.","og_url":"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-05-06T19:04:24+00:00","article_modified_time":"2024-05-06T19:04:25+00:00","og_image":[{"width":2360,"height":1622,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Nanobacterie secures strategic investment from EP Equity to advance prostate cancer treatment","datePublished":"2024-05-06T19:04:24+00:00","dateModified":"2024-05-06T19:04:25+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/"},"wordCount":319,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg","keywords":["Biotech","Financing","Oncology","Pharma","Technology Park"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/","url":"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/","name":"Nanobacterie secures strategic investment from EP Equity | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg","datePublished":"2024-05-06T19:04:24+00:00","dateModified":"2024-05-06T19:04:25+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"EP Equity Investment has acquired a 24.99% stake in Nanobacterie to advance the development of innovative treatments for prostate cancer.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/05\/Nanobacterie-Prostate-Cancer-Treatment-2360x1822-1.jpeg","width":2360,"height":1622,"caption":"As Nanobacterie prepares for clinical trials, EPEI's investment both validates their innovative approach and strengthens their ability to address critical global medical challenges."},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/nanobacterie-secures-strategic-investment-from-ep-equity-to-advance-prostate-cancer-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"Nanobacterie secures strategic investment from EP Equity to advance prostate cancer treatment"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/24214","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=24214"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/24214\/revisions"}],"predecessor-version":[{"id":24218,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/24214\/revisions\/24218"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/24215"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=24214"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=24214"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=24214"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}